Employees: 3,008
Size Arata (2733.T) is a Japan Health Care company (Medical Distributors) with a market value of $576M, the 992nd largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥2,602 on 18 Nov 2026.
Performance Over six months the shares fell 2.5%, against -5.4% for the median peer and -1.4% for the Japan market (cap-weighted) — 11th highest of 21 in its peer set.
Growth Revenue grew 2.5% over the last twelve months (peer median +3.9%); the operating margin is 1.1% (peer median 2.3%).
Valuation It trades at 12.0× forward earnings against a peer median of 18.2× (2nd cheapest of 10).
Price implies For today's price to make sense, revenue must grow about -6% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is -10 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 0.2 points above its cost of capital (5.0% WACC).
Next results Next results expected around 10 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥1.02T | ¥1.00T | ¥986B | ¥944B | ¥892B |
| Revenue growth | — | +2% | +4% | +6% | — |
| Gross profit | ¥98.7B | ¥97.3B | ¥96.2B | ¥92.4B | ¥86.8B |
| EBITDA | ¥16.8B | ¥18.1B | ¥19.8B | ¥19.1B | ¥17.4B |
| Net income | ¥8.80B | ¥10.1B | ¥10.4B | ¥10.3B | ¥8.22B |
| Free cash flow | n/a | ¥13.0B | ¥5.14B | ¥10.5B | ¥8.61B |
| Capital expenditure | n/a | ¥8.53B | ¥6.16B | ¥5.61B | ¥4.33B |
| Total debt | ¥53.0B | ¥53.7B | ¥36.0B | ¥38.4B | ¥43.3B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 2733.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +0.2% | -4.1% | 7th highest of 21 |
| 6-month return | -2.5% | -5.4% | 11th highest of 21 |
| Distance from 52-week high | -17.8% | -22.4% | 9th highest of 21 |
| Revenue growth (TTM) | +2.5% | +3.9% | 9th lowest of 21 |
| Operating margin | 1.1% | 2.3% | 9th lowest of 21 |
| Forward P/E | 12.0× | 18.2× | 2nd cheapest of 10 |
| Growth the price implies (Req g, 7 yrs) | -6.2% | 0.0% | 4th least demanding of 16 |
| Growth delivered (Del g) | +3.8% | +5.7% | 7th lowest of 16 |
| Hurdle (Req g minus delivered) | -9.9 pp | -5.0 pp | 4th least demanding of 16 |
| ROIC minus cost of capital | +0.2 pp | -0.5 pp | 9th highest of 21 |
| Net debt / EBITDA | 1.8× | -1.2× | 3rd most indebted of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Arata 2733.T | Japan | $576M | -3% | +3% | 1% | 12.0× | -6.2% | +3.8% |
| Shanghai New World 600628.SS | China | $573M | -10% | -2% | 6% | n/a | -1.6% | +1.0% |
| GKHT Medical Technology 301370.SZ | China | $525M | -24% | -11% | 1% | n/a | 13.1% | +7.5% |
| Shanghai Lily & Beauty Cosmetics 605136.SS | China | $449M | -28% | +5% | 2% | n/a | 21.1% | -18.1% |
| Thalys Medical Technology 603716.SS | China | $446M | -33% | -43% | -18% | n/a | n/a | n/a |
| Neuca NEU.WA | Poland | $795M | -9% | +8% | 2% | 15.3× | 5.3% | +8.1% |
| Gongwin Biopharm 6617.TWO | Taiwan | $412M | +87% | +12% | -530% | n/a | n/a | n/a |
| Shenzhen Neptunus Bioengineering 000078.SZ | China | $411M | -48% | -22% | -1% | n/a | 58.3% | -7.8% |
| Excelsior Medical 4104.TW | Taiwan | $404M | +5% | +11% | 8% | n/a | -1.2% | +5.7% |
| Vital KSK 3151.T | Japan | $399M | -1% | +3% | 0% | n/a | 4.7% | +2.6% |
| Shanghai Haohai Biological Technology 688366.SS | China | $878M | -24% | -9% | -2% | 16.2× | 16.9% | +13.2% |
| Entero Healthcare Solutions ENTERO.NS | India | $925M | +60% | +35% | 4% | 47.7× | 24.7% | +29.9% |
| Arjo ARJO-B.ST | Sweden | $974M | +42% | 0% | 8% | 21.1× | -1.0% | +3.9% |
| Guangxi LiuYao 603368.SS | China | $975M | +1% | +2% | 5% | 9.5× | -9.7% | +6.0% |
| Shanghai Universal Biotech 301166.SZ | China | $337M | -15% | +15% | -4% | 25.3× | n/a | n/a |
| Nanjing Pharmaceutical 600713.SS | China | $999M | -2% | +3% | 2% | n/a | n/a | n/a |
| Nagaileben 7447.T | Japan | $319M | 0% | +1% | 21% | 18.2× | -12.7% | -0.4% |
| Shanghai C and D INNOSTIC Medical Technology 301584.SZ | China | $1.06B | -33% | +8% | 3% | n/a | -2.7% | +17.9% |
| DocMorris DOCM.SW | Switzerland | $1.08B | +169% | +11% | -8% | n/a | n/a | n/a |
| AS ONE 7476.T | Japan | $1.10B | +25% | +10% | 12% | 18.4× | 0.0% | +6.3% |
| Shinva Medical Instrument 600587.SS | China | $1.10B | -10% | +6% | 5% | 13.4× | -6.9% | +1.2% |